Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?

Amy B. Heimberger, John H. Sampson

Research output: Contribution to journalReview articlepeer-review

82 Scopus citations


With the recent approval by the FDA of an immunotherapy for prostate cancer and another positive immunotherapy trial in melanoma, immunotherapy may finally be coming of age. So what will it take for it to become part of the standard treatment for glioblastoma? To put this question into perspective, we summarize critical background information in neuro-immunology, address immunotherapy clinical trial design, and discuss a number of extrinsic factors that will impact the development of immunotherapy in neuro-oncology.

Original languageEnglish (US)
Pages (from-to)3-13
Number of pages11
Issue number1
StatePublished - Jan 2011
Externally publishedYes


  • Clinical trial
  • Glioblastoma multiforme
  • Immunotherapy
  • Malignant gliomas

ASJC Scopus subject areas

  • Clinical Neurology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?'. Together they form a unique fingerprint.

Cite this